After Hours Most Active for Jan 7, 2025 : SANA, T, NVDA, INTC, GETY, WIMI, SNAP, AAPL, PSTX, VZ, MDT, SARO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 After Hours Performance: The NASDAQ 100 is up 28.17 points to 21,201.21 with a total after-hours trading volume of 186,500,748 shares.
Most Active Stocks: Sana Biotechnology leads with a significant increase, while other notable stocks include AT&T, NVIDIA, and Intel, with varying performance in after-hours trading.
Analyst Views on SANA
Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.670
Low
5.00
Averages
7.00
High
9.00
Current: 4.670
Low
5.00
Averages
7.00
High
9.00
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
